Kobe, Japan

Takeshi Kuboyama


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Takeshi Kuboyama

Introduction

Takeshi Kuboyama is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of chemistry, particularly in the development of compounds used in various reactions. His work has implications for advancements in medical imaging and biochemistry.

Latest Patents

Takeshi Kuboyama holds 1 patent that focuses on an F-labeled azide compound. This compound is particularly useful in the Huisgen reaction, enabling F-labeling even when only a small quantity of alkyne compound is available as a counterpart substrate. The invention allows for the application of positron emission tomography (PET) to peptides or oligonucleotides, facilitating F-labeling at any site of an oligonucleotide other than the 5' end or 3' end. This innovation includes a reagent for F-labeling and a method for F-labeling an alkyne compound using the same.

Career Highlights

Takeshi Kuboyama is associated with Riken Corporation, a leading research institution in Japan. His work at Riken has allowed him to explore various innovative solutions in the field of chemistry. His contributions have been recognized within the scientific community, showcasing his expertise and dedication to research.

Collaborations

Takeshi has collaborated with esteemed colleagues such as Yasuyoshi Watanabe and Masaaki Suzuki. These collaborations have further enriched his research and have led to advancements in their respective fields.

Conclusion

Takeshi Kuboyama's innovative work in the development of F-labeled azide compounds demonstrates his significant impact on the field of chemistry. His contributions continue to pave the way for advancements in medical imaging and biochemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…